Accelerating DoD’s Fielding of Prototypes for
Medical Countermeasures
NEW OPPORTUNITIES
New RPP Released:
RPP-24-01: Gene-Encoded MCM Development and Response Platform
RPP-24-02: Reactivating Nerve Agent Treatment System (RNATS) Prototype
New Draft RPPs Released:
Draft SOO: Broad Spectrum Therapeutics
New RFIs Released:
None at this time
MCDC offers a wide variety of
members and funding opportunities
Current Members
Awards
Funded to Date
Non-Traditional Members
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
WHO CAN JOIN?
Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.
• Traditional Contractors
• Non-Traditionals (Companies that don’t typically participate in Federal R&D)
• Academia
• Non-Profit/Not-For-Profit Research Institutions

PREVENTION
Prophylaxis, pretreatment, and post-exposure prophylaxis

DIAGNOSTICS
Systems and devices to identify CBRN agents and assist in making medical decisions

TREATMENT
Therapeutics for post-exposure and post-symptomatic